RxDoctor Payments Data

Larissa Stewart, MD

Dermatology · Spring, TXNPI 1922307693

Payments from drug & device makers

$14,452in general payments, 2019–2025

Across 492 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$4K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • Arcutis Biotherapeutics, Inc.$739
  • Lilly USA, LLC$726
  • Novartis$717
  • plus $5K from 20 others

What the payments were for

  • Speaking & faculty fees$3,20022%
  • Food & beverage$10,91876%
  • Education$3342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,452 in reported general payments places this provider in the 75th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$279,673
Medicare patients
900
Services billed
4,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab12$102,521
Dupixent SyringeDupilumab18$65,106
OtezlaApremilast12$64,817
Clobetasol Propionate93$2,649
Fluorouracil45$2,559
Doxycycline Hyclate31$1,487
Metronidazole38$1,468
Desonide30$1,320
Ketoconazole127$1,292
Mupirocin178$1,231
Triamcinolone Acetonide147$1,173
ValacyclovirValacyclovir Hcl30$772
Clindamycin Phosphate28$705
Nystatin49$672
Tacrolimus11$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$356$64,81712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Spring

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →